Table 3.

Outcomes for outpatient nirmatrelvir plus ritonavir users versus matched controls

		Nirmatrelvir plus ritonavir (n=5542)		Control (n=54 672)		Nirmatrelvir plus ritonavir vs control
		Crude incidence rate (events per 100 000 person-days)		Crude incidence rate (events per 100 000 person-days)		HR (95% CI)*	p value
		Estimate (95% CI)	Person-days	Estimate (95% CI)	Person-days
All-cause mortality		4·2 (2·6–6·3)	528 328	11·6 (10·8–12·6)	5 471 588	0·34 (0·22–0·52)	<0·0001
Hospitalisation		48·5 (42·6–54·9)	507 655	61·0 (58·9–63·2)	5 221 023	0·76 (0·67–0·86)	<0·0001
In-hospital disease progression		4·6 (2·9–6·8)	526 844	7·5 (6·8–8·3)	5 462 351	0·57 (0·38–0·87)	0·0083
	In-hospital death	1·5 (0·7–3·0)	528 328	5·8 (5·2–6·4)	5 471 588	0·25 (0·12–0·50)	0·0001
	Invasive mechanical ventilation	0·8 (0·2–1·9)	527 944	1·2 (0·9–1·5)	5 468 815	0·62 (0·23–1·72)	0·36
	Intensive care unit admission	3·2 (1·9–5·2)	526 926	1·9 (1·6–2·3)	5 463 019	1·58 (0·95–2·63)	0·078

HR=hazard ratio.

^*HRs greater than 1 indicate that nirmatrelvir plus ritonavir users had higher risk of outcome compared with the matched control group.